# Isomorphic Labs raises $2.1B to push AI-designed drugs into the clinic
> DeepMind spin-out's Series B, second-largest biotech round ever, funds its IsoDDE engine and a first in-house trial by end-2026

**Meta:** type: event · date: 2026-05-12 · heads: 誰の金か, 長期戦 · 12 takes · 3 lenses · 6 regions

## Summary

[Isomorphic Labs](/ja/entity/isomorphic-labs), the [DeepMind](/ja/entity/google-deepmind) drug-discovery spin-out, announced a $2.1B Series B on 12 May 2026, led by Thrive Capital with Alphabet, GV, CapitalG, Temasek, [Abu Dhabi's MGX](/ja/entity/mgx) and the UK Sovereign AI Fund, its first outside capital, taking total funding to ~$2.6B. It is described as the second-largest biotech round ever. The money scales [IsoDDE](/ja/entity/ai-drug-design), the firm's post-[AlphaFold 3](/ja/entity/alphafold) drug-design engine, which it says doubles AlphaFold 3 accuracy on the hardest protein-ligand cases (50% vs 23.3%). CEO Demis Hassabis now targets the firm's first in-house candidates in human trials by end-2026, conceding he had "misspoke" on an earlier 2025 target. Isomorphic runs paid programs with Novartis, Eli Lilly and J&J.

## By the numbers

- $2.1B, Series B; ~$2.6B total raised to date.
- 50% vs 23.3%, IsoDDE vs AlphaFold 3 accuracy on <20%-training-similarity protein-ligand cases.
- End-2026, Hassabis's target for first in-house candidate in human trials.
- Up to $1.7B, milestone value of the Eli Lilly partnership.
- 3, pharma partners (Novartis, Lilly, J&J).

## Why it matters

The round is a heavy bet that AI-native discovery can compress the cost and timeline of drug design rather than just predicting structures. Sovereign funds (Temasek, MGX, UK) and Alphabet are exposed. Whether IsoDDE produces a clinic-ready molecule from Isomorphic's own pipeline is now the test the field is watched on.

## What to watch

- Whether a first in-house candidate actually enters Phase 1 by end-2026.
- Milestone payments triggering on the Novartis/Lilly/J&J programs.
- Independent benchmarks of IsoDDE against AlphaFold 3 and rival engines.

## Regional takes (batched by bias / lens)

### unlabelled
- **Isomorphic Labs (company release)** (United Kingdom, en) — Isomorphic's own announcement of the $2.1B Series B, led by Thrive Capital with Alphabet, GV, CapitalG, Temasek, MGX and the UK Sovereign AI Fund; capital earmarked to scale the IsoDDE drug-design engine and push its pipeline toward the clinic.
  Source: https://www.isomorphiclabs.com/articles/isomorphic-labs-announces-series-b-investment-round
- **Isomorphic Labs (IsoDDE technical note)** (United Kingdom, en) — The IsoDDE technical write-up: the engine reportedly doubles AlphaFold 3 on hard (<20% training-similarity) protein-ligand structure prediction, 50% vs 23.3% accuracy.
  Source: https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier
- **Reuters / Yahoo Finance** (United States, en) — 
  Source: https://finance.yahoo.com/sectors/healthcare/articles/isomorphic-labs-raises-2-1-164235060.html
- **PR Newswire** (United States, en) — 
  Source: https://www.prnewswire.com/news-releases/isomorphic-labs-secures-2-1-billion-funding-to-scale-its-ai-drug-design-engine-302769674.html
- **BioPharm International** (United States, en) — 
  Source: https://www.biopharminternational.com/view/isomorphic-labs-raises-2-1-billion-to-expand-ai-driven-drug-discovery-platform
- **Galen Growth** (Singapore, en) — 
  Source: https://www.galengrowth.com/isomorphic-labs-2-1bn-series-b-ai-drug-discovery/
- **Ventureburn** (South Africa, en) — 
  Source: https://ventureburn.com/isomorphic-labs-raises-2-1b-for-ai-drug-discovery/
- **YourStory** (India, en) — 
  Source: https://yourstory.com/ai-story/isomorphic-labs-ai-drug-discovery-series-b-2026
- **The AI Insider** (Global, en) — 
  Source: https://theaiinsider.tech/2026/05/13/isomorphic-labs-announces-2-1b-funding-to-scale-its-ai-drug-design-engine/
- **Wilson Sonsini (advisor note)** (United States, en) — 
  Source: https://www.wsgr.com/en/insights/wilson-sonsini-advises-isomorphic-labs-on-dollar21-billion-series-b-investment-round.html

### industry / capital-markets
- **BioSpace** (United States, en) — Frames the round as the second-largest biotech financing ever, total funding now ~$2.6B, and notes Hassabis's revised target: first in-house candidates in human trials by end-2026 after he conceded he had 'misspoke' on the earlier 2025 date.
  > "AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever."
  Source: https://www.biospace.com/business/ai-fueled-isomorphic-bags-2-1b-the-second-largest-biotech-round-ever

### drug-development / pipeline
- **FierceBiotech** (United States, en) — Reports the capital funds the next-generation IsoDDE model and Isomorphic's joint programs with Novartis, Eli Lilly and J&J, including a Lilly deal worth up to $1.7B in milestones, as it races to be the first AI-native firm into Phase 1 from its own pipeline.
  > "Alphabet's AI biotech Isomorphic Labs bags $2.1B series B to fuel next-gen drug design model."
  Source: https://www.fiercebiotech.com/biotech/alphabets-ai-biotech-isomorphic-labs-bags-21b-series-b-fuel-next-gen-drug-design-model

## Across the graph
- Related: [[newlimit-series-c-reprogramming-2026]], [[evo2-generative-genome-2026]], [[dna-synthesis-screening-letter-2026]]
- Entities: Isomorphic Labs, Alphafold, Google Deepmind, AI Drug Design, Temasek, Mgx

---
Canonical: https://rbtfl.xyz/ja/n/isomorphic-labs-series-b-2026